N ew Year's Eve in 2014 will mark the fivehundredth anniversary of the birth of Andreas van Wesel, commonly known as Vesalius, author of De humani corporis fabrica 1 , a treatise almost as influential in its time as was On the Origin of Species over three centuries later. Vesalius pioneered the rigorous study of human anatomy and introduced experimental observation into medical education as a substitute for hearsay. The late Victor McKusick, who helped to create the Human Genome Project and mapped the first human autosomal gene, called gene mapping "neo-Vesalian" 2 , as it represented an anatomy of the genome, similar to Vesalius' anatomy of the body, for finding genes. Vesalius was more than a mapper, though: he challenged the dogma of both Galen and Aristotle on the anatomy of blood circulation by using the arrangement of structures in the body to correctly deduce their functions. Similarly, the particular order of genes on chromosomes and the arrangement of the chromosomes themselves have only recently been found to be meaningful biologically, not just as a map.
I suggest here that epigenomics-that is, the genome-scale study of epigenetics-has transformed genome science by showing that the organization of the genome is important for gene function, just as Vesalius showed that the organization of anatomic structures allowed the function of organs. Moreover, the combination of new epigenomic tools with conventional genetics, and a new mathematical language for their interface, may have as much impact on understanding of human disease as did Vesalius' anatomy a half-millennium ago.
Epigenomics provides a functional anatomy of the genome Epigenomics has helped to reveal several surprising large-scale functional relationships among genes themselves and the surrounding nongenic DNA, previously hinted at by the β-globin cluster. One is the generality of large (tens to thousands of kilobases) genomic regions regulating gene expression. Although the β-globin gene cluster had been studied for decades 3 and progressive chromatin changes had been linked to globin gene switching during development 4 , the generality and size of multigene chromatin domains emerged only with large-scale epigenomic mapping. As increasing numbers of imprinted genes were found, it was discovered that they were organized in gene clusters, often with common regulatory elements, such as CCCTC binding factor (CTCF) binding sites 5 . With the advent of genome-scale mapping of histone modifications, many large regions of heterochromatin modifications have been found, such as specific modifications associated with the inactive X chromosome 6 . Moreover, large autosomal regions of heterochromatin modification across Hox gene clusters have been determined to be more highly conserved across species than the underlying DNA sequence and do not simply correspond to exonic boundaries 7 . Thus, epigenomic studies have revealed that the functional genome is at least an order of magnitude greater in scope than what was suspected on the basis of the sequence alone. Epigenomics has provided the genome with the kind of functional anatomy that Vesalius gave gross anatomy five centuries ago.
Another unexpected large-scale genomic relationship is frequent intra-and interchromosomal interactions mediated by chromatin proteins. These were discovered through chromatincapture methods, described in detail elsewhere in this issue 8 , designed to preserve chromatinmediated interactions over long distances. DNA loop structures, mediated by chromatin, highly dynamic and surprisingly common, are associated with function. For example, several interleukin genes in the 200-kilobase (kb) mouse TH2 cytokine locus, when transcriptionally active, are folded into numerous loops anchored by special AT-rich sequence-binding protein (SATB) at their bases 9 . Remarkably, trans interactions between chromosomes involve some of the same sequences that epigenetically regulate imprinted gene domains, such as the H19 differentially methylated region, and may act through transvection to regulate genes in trans 10 .
A recent example of large-scale genomic organization mediated by chromatin is the link between long RNAs, heterochromatin modification and gene activity. At the 'Biology of Genomes' meeting held at Cold Spring Harbor, New York, USA on 11-15 May 2005, Tom Gingeras of Cold Spring Harbor Laboratory asked for a wager on the number of genes that will ultimately be agreed upon, arguing that the nearly 50% of the genome that may be untranslated RNA will be proved Epigenomics reveals a functional genome anatomy and a new approach to common disease
Andrew P Feinberg
Epigenomics provides the context for understanding the function of genome sequence, analogous to the functional anatomy of the human body provided by Vesalius a half-millennium ago. Much of the seemingly inconclusive genetic data related to common diseases could therefore become meaningful in an epigenomic context. and in comparisons of tissues derived from different germ layers 26 . Thus, the language of epigenomic organization seems to be common for normal development and for disease, just as the language of anatomy is common for normal and abnormal physiology.
Increasing appreciation of the importance of large-scale epigenetic control in regulating gene function has influenced how disease-based genomic studies are being organized. Although published genome-scale studies represent only about 2% of cancer epigenetics, the rate of increase over the past five years of cancer epigenomic studies is more than double that of conventional gene-based analyses of cancer (Fig.  1) . The same relative increase in genome-scale studies also seems to apply in the nascent field of noncancer human disease epigenetics, such as epigenetics of cardiovascular, immunological and neuropsychiatric disease 27, 28 . These differences are driven in part by the availability of new technology, of course, but also by the growing realization that variation in both DNA methylation and chromatin are widespread across the genome and may be organized into large genomic domains.
Another important factor driving such 'disease epigenomics' is the relatively limited yield to date of conventional single-nucleotide polymorphism (SNP)-based genetic analysis in explaining most common human diseases. As has been widely described in both scientific 29, 30 and lay publications 31 , it was anticipated a decade ago that genetic analysis would be much more successful at attributing risk of disease to specific genetic markers.
How is epigenomics transforming the search for genetic causes of common human diseases? Many have suggested that environmentally driven epigenetic variation may be an important contributing factor in disease risk, particularly as a surrogate for mutational change [32] [33] [34] (Table 1) .
But researchers should also consider another dimension to this epigenetic argument for common disease, an aspect that has received comparatively less attention. Because the actual 'genome anatomy' target for disease is probably much larger than scientists previously realized-perhaps involving more than half of the genome-and because understanding of the normal function of this genome anatomy requires epigenomics, it is possible that much of what appears to be negative genetic-association data could become meaningful in an epigenomic context ( Table 1) . For example, most genome-wide association studies (GWAS) identify not genes, but nearby regions or intergenic deserts. Yet these same regions frequently harbor differentially methylated regions that discriminate tissue types or distinguish cancer over large gene regions 19 . That such networks have a general role in organizing the genome functionally is suggested by the identification of chromosome territories and the spatial proximity of gene-rich chromosomes 20 .
Epigenomics may supersede single-gene epigenetic disease research
Just as epigenomics provides a functional anatomy of the normal genome, genome-scale studies of epigenetic disease are helping us understand epigenetic pathology. And just as cancer was the vanguard for gene-specific disease epigenetics 21 , genome-scale epigenetic studies of disease have also focused first on cancer, revealing much more genetic pathology than was suggested by candidate-gene approaches. For example, methylation changes can affect large genomic regions in colorectal cancer 22 , and widespread methylation changes are even more striking outside of the usually examined CpG islands (i.e., in shores and gene bodies) 23 . Similarly, it came as a surprise to most when widespread alterations in histone acetylation and methylation were found to be ubiquitous in cancer 24 . Stem cells, the focus for a wide range of both basic and applied research on disease, have shown promiscuous methylation differences from somatic cells on a genome-wide scale, notably including differences at non-CpG sites 25 . Remarkably, the sites of differential methylation largely overlap, with strong statistical significance, across physiological states-the same sites appear, for example, in normal cells compared with cancer cells, in stem cells compared with differentiated cells functional 11 . Growing evidence indicates that much of this RNA mediates chromatin structure. For example, antisense RNAs appear to establish heterochromatin in mammalian genes, independently of Dicer and the post-translational microRNA machinery 12 . These regions may span >100 kb 12 , affect multiple genes and involve Argonaut-family proteins 13 . An exciting recent discovery is the role of long intergenic noncoding RNAs (lincRNAs) in establishing heterochromatin. For example, HOTAIR is a lincRNA that retargets PRC2 over HOX domains, leading to marked changes in gene expression relevant to cancer progression 14 .
Finally, large organized chromatin lysine (K) modifications (or LOCKs) have been shown to organize the genome into very large blocks (hundreds to thousands of kilobases), some of which are differentiation-specific in their location and extent and correspond to lamin-associated domains (LADs) [15] [16] [17] . These very large regions may provide a dynamic mechanism for functional organization of the genome and are altered in cancer 15 .
Large-scale mapping studies offer additional clues that many such large-scale epigenetic networks profoundly influence cellular development and genome function. For example, CTCF, which mediates H19 imprinting, seems to play a general role in defining the boundaries of functional gene regions 18 . Likewise, target genes of Polycomb, a protein thought to be involved in stable gene silencing, may alternate between functionally active and silent states c o m m E n ta r y samples or even single cells, and enrichment of small chromosomal fragments for biochemical analysis of chromatin 41 . A new epigenetic epidemiology will need to be crafted. Research can no longer consider genetic variation in isolation when looking for disease relationships. Samples in ongoing and future large-scale cohorts must be preserved to allow analysis of DNA methylation and chromatin. But retrospectively, a great deal can be added to existing cohort studies, as DNA methylation is stable over decades. Much of the existing genetic data might be made clearer by supplementing those studies with epigenomic analysis. New cohort sampling should include standard sources, such as lymphocytes, but also, as much as possible, target tissues affected by the disease.
Additionally, we need to develop new statistical and epidemiological tools for disease epigenomics and for its synthesis with conventional genetic analysis. For example, unlike SNPs, epigenetic variation is inherently quantitative and thus does not lend itself to simple allele designation (for example, quantitative levels of DNA methylation or Polycomb complex members). The quantitative nature of epigenome variation can help explain complex traits with a smaller number of contributing loci, as they do not necessarily require as many of the additive signals originally proposed by R.A. Fisher 42 . Such an approach is being applied, for example, to the analysis of quantitative traits associated with VMRs 39 .
The apparent additional complexity that epigenomics brings to genetics may seem daunting. But I don't think Vesalius would have been intimidated, and I know Victor would have been delighted.
Future technology development
What potential areas for future technology development will fuel growth in this area? Of course, as in non-epigenetic genome science, all roads lead to sequencing, including bisulfite genome-scale sequencing for DNA methylation. The rollout of inexpensive, comprehensive and high-throughput single-molecule sequencing has been slower than promised, and second-generation sequencing is still impractical for large-scale epidemiological studies involving thousands of patients, except for capture-based methods, such as padlock probes 40 . The dilemma in capture-based studies is that although they offer enormous advantages in throughput, single-base resolution and allele-specific data, they will not reveal regions of differential methylation where we do not already know to look-a problem that may be vast as epigenomics is applied to an ever increasing number of diseases. At the same time, high-throughput sequencing is relatively cheap now for examining chromatin modifications-but that is true only for studies working, for example, with modifications on a fairly small fraction of the genome purified by chromatin immunoprecipitation. For large regional changes, such as LOCKs, there are cost limitations similar to those for wholegenome bisulfite sequencing.
An important advance will come from reagents, such as the arrays from Illumina (San Diego) and others, that are cheap and amenable to processing by typical university core laboratories. For example, a soon-to-be-released methylation chip from Illumina will provide ~450,000 targets, including all CpG islands and shores, as well as DNase-hypersensitive sites and other regions identified and curated for this purpose by a consortium of laboratories organized by Tom Hudson of McGill University in Montreal. Although this reagent may not be next year's or even this year's most comprehensive tool, 450,000 targets isn't bad-and such cooperative approaches open epigenomic research to any general laboratory, a very exciting development. Other exciting technological initiatives include epigenomic analysis of microdissected from normal cells. They are also the canonical regions for lincRNAs that help establish chromatin structure and normal gene function. Furthermore, gene deserts may promote trans associations of chromosomes in epigenetic regulation 35 . Another way in which diseaseassociated DNA sequence variants might affect disease risk is through their linkage to DNA sequences that regulate DNA methylation, chromatin modification or binding factors. Substantial association of SNPs with DNA methylation has already been found 36, 37 .
An additional possibility my group has proposed is that DNA sequence variants themselves might affect the stochastic or environmentally influenced variance in the epigenome. According to this model, individuals in a complex species would gain an evolutionary advantage by including alleles for increased epigenetic variation per se (i.e., genetic alleles that increase epigenetic variance without affecting the mean) 38 . This would be like an evolutionary 'hedging one's bet' and would confer an advantage for genes in pathways whose environment changes epochally (e.g., in response to the abundance of food and water). Examining inbred mice from the same litter and living in the same cage, we identified hundreds of variably methylated regions (VMRs) that are highly enriched by functional annotation for key genes in development and embryonic pattern formation 38 . Thus, development itself, which is regulated by epigenetics, probably includes a great deal of stochasticity at the epigenetic level. Genetic variants that increase this developmental plasticity at specific targets may confer an evolutionary advantage but might be deleterious to some individuals after a recent epochal change in the environment, such as the recent Western diet 38 . Intriguingly, several VMRs have recently been linked to body mass index 39 .
Finally, researchers are only beginning to understand the role of LOCKs and LADs in functional genome organization. Their assessment in disease will require robust genome-scale approaches to native chromatin measurement and availability of clinical specimens permitting such analyses (Table 1) . 
